Researchers at the University of Copenhagen Lundbeck and University of Tokyo have developed a technology that can detect advanced forms of acute myelogenous leukemia (AML) a form of cancer that frequently shows up in the kidneys of people with diabetes. AFib is a common form of kidney cancer and the sixth leading cause of cancer-related deaths in the world.

The new technology which should be tested in clinical settings in the near future consists of a tiny cell recording chip contained in a hydrogel that has been manufactured in Japan by the Zentrum Hjorth Corporation. The chip is placed between two blood filtration membranes and it is sandwiched between them. The membranes are then tightly packed in a nanostructure that has been presented in a liquid. This procedure has been studied at the Zentrum for several years but the particular invention by the researchers has only now been published in scientific journals.

By implanting the chip with cells the researchers been able to detect leukemia in a mouse model for the first time in the history of medicine. The result shows the potential which the researchers hope to have in a radiotherapy field.

The treatment could have a huge impact on the field and effective treatments says Professor Atte Prnen of the University of Copenhagen who is directly involved in the research.

AMS is a rare aggressive form of cancer in which the patients blood cells bounce back into their normal forms in their absence of a normal stem cell hence the popular horse-breeder illustration for this disease.

A number of researchers have used CRISPR -; a type of gene editing -; to disrupt the genes of cancerous cells causing the cancer to die. However the successful application of this in vitro procedure in animal models is very limited and studies only so far have proven the effectiveness of this technique in stopping AML. The implementation of the nano-technology in person is therefore a step toward a much more scientifically accurate cancer diagnosis. Before the monitoring is done patients must be followed for the entire duration of the third year. The monitoring is specifically designed to enable doctors to detect if the patient will become symptomatic for the disease alerting them in advance of the first symptoms or not and to fight it if it is present at the beginning of the disease.

The patients will then be identified by the biomarker and if a diagnosis is positive the patient will be switched immediately to the therapy shown in the study. In the case of AML-positive patients the therapy for two to four years should be started. However a diagnosis of EBCL is required for the detection and treatment of the diseases; a very demanding country where the presence of doctors and nurses is difficult to control. On the same point the patient will be told: Im fine and I need to go home and then would be asked to refrain from long-term follow-ups for at least six months. After the six-month break the patient then would return to regular life.